FDA Approves Studies at Columbia of Plasma Therapy for COVID-19

April 23, 2020

The U.S. Food and Drug Administration has granted approval to the Center for Infection and Immunity (CII) at Columbia University Mailman School of Public Health to launch clinical trials to determine whether blood plasma from COVID-19 survivors can be used to prevent infections in unexposed healthcare workers and first responders, high-risk individuals, and close contacts of COVID-19 patients, and whether it can treat COVID-19 patients with severe disease.

The study is funded with $2.5 million in support from Amazon.